Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2018 Dec 27. doi: 10.1001/jamaoncol.2018.5801. [Epub ahead of print]

PMID:
30589920
2.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
3.

Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.

Hammerich KH, Donahue TF, Rosner IL, Cullen J, Kuo HC, Hurwitz L, Chen Y, Bernstein M, Coleman J, Danila DC, Metwalli AR.

Urol Oncol. 2017 Jul;35(7):460.e21-460.e28. doi: 10.1016/j.urolonc.2017.02.001. Epub 2017 Apr 11.

PMID:
28410987
4.

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.

Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, Danila DC, Dugan L, Johnson A, Heller G, Fleisher M, Dittamore R.

Eur Urol. 2017 Jun;71(6):874-882. doi: 10.1016/j.eururo.2016.11.024. Epub 2016 Dec 12.

5.

A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

O'Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC, Laudone VP, Bochner BH, Sheinfeld J, Dayan ES, Bellomo LP, Sjoberg DD, Heller G, Zelefsky MJ, Eastham JA, Scardino PT, Scher HI.

Urology. 2017 Apr;102:164-172. doi: 10.1016/j.urology.2016.10.044. Epub 2016 Nov 22.

7.

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.

Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS.

Eur Urol. 2016 Dec;70(6):985-992. doi: 10.1016/j.eururo.2016.05.023. Epub 2016 Jun 9.

8.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, de Bono JS.

J Clin Oncol. 2015 Apr 20;33(12):1348-55. doi: 10.1200/JCO.2014.55.3487. Epub 2015 Mar 23.

9.

Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.

Autio KA, Farooki A, Glezerman IG, Chan A, Schneider CW, Barr HC, Seyboth BM, Kampel LJ, Danila DC, Rathkopf DE, Slovin SF, Scher HI, Morris MJ.

Clin Genitourin Cancer. 2015 Aug;13(4):e305-e309. doi: 10.1016/j.clgc.2014.11.008. Epub 2014 Nov 22. No abstract available.

10.

Organoid cultures derived from patients with advanced prostate cancer.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y.

Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4.

11.

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, de Bono J, Danila DC.

Br J Cancer. 2013 Nov 12;109(10):2579-86. doi: 10.1038/bjc.2013.619. Epub 2013 Oct 29.

12.

Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay.

Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, Ionescu-Zanetti C.

Transl Oncol. 2013 Oct 1;6(5):528-38. eCollection 2013.

13.

Theranostic immunoliposomes for osteoarthritis.

Cho H, Stuart JM, Magid R, Danila DC, Hunsaker T, Pinkhassik E, Hasty KA.

Nanomedicine. 2014 Apr;10(3):619-27. doi: 10.1016/j.nano.2013.09.004. Epub 2013 Oct 2.

14.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI.

J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.

15.

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI.

Eur Urol. 2014 Jun;65(6):1191-7. doi: 10.1016/j.eururo.2013.07.006. Epub 2013 Jul 26.

16.

Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?

Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI.

Semin Oncol. 2013 Jun;40(3):375-92. doi: 10.1053/j.seminoncol.2013.04.008. Review.

PMID:
23806501
17.

Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.

Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA.

Oncologist. 2013;18(2):163-73. doi: 10.1634/theoncologist.2012-314. Epub 2013 Jan 22.

18.

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, de Bono JS.

Lancet Oncol. 2012 Nov;13(11):1114-24. doi: 10.1016/S1470-2045(12)70372-8. Epub 2012 Oct 9.

19.

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI.

Cancer Res. 2012 Dec 1;72(23):6142-52. doi: 10.1158/0008-5472.CAN-12-1335. Epub 2012 Sep 12.

20.

Circulating tumors cells as biomarkers: progress toward biomarker qualification.

Danila DC, Pantel K, Fleisher M, Scher HI.

Cancer J. 2011 Nov-Dec;17(6):438-50. doi: 10.1097/PPO.0b013e31823e69ac. Review.

21.

Gated and near-surface diffusion of charged fullerenes in nanochannels.

Grattoni A, Fine D, Zabre E, Ziemys A, Gill J, Mackeyev Y, Cheney MA, Danila DC, Hosali S, Wilson LJ, Hussain F, Ferrari M.

ACS Nano. 2011 Dec 27;5(12):9382-91. doi: 10.1021/nn2037863. Epub 2011 Nov 14.

PMID:
22032773
22.

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.

Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.

Eur Urol. 2011 Nov;60(5):897-904. doi: 10.1016/j.eururo.2011.07.011. Epub 2011 Jul 14.

23.

Circulating tumor cells as biomarkers in prostate cancer.

Danila DC, Fleisher M, Scher HI.

Clin Cancer Res. 2011 Jun 15;17(12):3903-12. doi: 10.1158/1078-0432.CCR-10-2650. Review.

24.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.

25.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS.

J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16.

26.

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.

J Clin Oncol. 2010 Mar 20;28(9):1496-501. doi: 10.1200/JCO.2009.25.9259. Epub 2010 Feb 16.

27.

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.

Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2009 Mar 15;15(6):2091-7. doi: 10.1158/1078-0432.CCR-08-2036. Epub 2009 Mar 10.

28.

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H.

Clin Chem. 2009 Apr;55(4):765-73. doi: 10.1373/clinchem.2008.117952. Epub 2009 Feb 20.

29.

Controlled loading of building blocks into temporary self-assembled scaffolds for directed assembly of organic nanostructures.

Banner LT, Danila DC, Sharpe K, Durkin M, Clayton B, Anderson B, Richter A, Pinkhassik E.

Langmuir. 2008 Oct 21;24(20):11464-73. doi: 10.1021/la801755b. Epub 2008 Sep 10.

PMID:
18781782
30.

Directed assembly of sub-nanometer thin organic materials with programmed-size nanopores.

Danila DC, Banner LT, Karimova EJ, Tsurkan L, Wang X, Pinkhassik E.

Angew Chem Int Ed Engl. 2008;47(37):7036-9. doi: 10.1002/anie.200801814. No abstract available.

PMID:
18677728
31.

Increasing permeability of phospholipid bilayer membranes to alanine with synthetic alpha-aminophosphonate carriers.

Danila DC, Wang X, Hubble H, Antipin IS, Pinkhassik E.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2320-3. doi: 10.1016/j.bmcl.2008.02.081. Epub 2008 Mar 6.

PMID:
18353645
32.

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Dec 1;13(23):7053-8.

33.

Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings.

Maegawa RO, Hussain S, Danila DC, Teruya-Feldstein J, Maki RG, O'Connor OA.

Leuk Lymphoma. 2007 Oct;48(10):2071-4. No abstract available.

PMID:
17917976
34.

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Apr 1;13(7):2023-9.

35.

A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells.

Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A.

J Clin Endocrinol Metab. 2003 Nov;88(11):5119-26.

PMID:
14602737
36.

Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.

Danila DC, Zhang X, Zhou Y, Haidar JN, Klibanski A.

J Clin Endocrinol Metab. 2002 Oct;87(10):4741-6.

PMID:
12364468
37.

Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis.

Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A.

J Clin Endocrinol Metab. 2002 Mar;87(3):1262-7.

PMID:
11889197
38.

Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.

Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A.

J Clin Endocrinol Metab. 2001 Jul;86(7):2976-81.

PMID:
11443154
39.

Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling.

Zhou Y, Sun H, Danila DC, Johnson SR, Sigai DP, Zhang X, Klibanski A.

Mol Endocrinol. 2000 Dec;14(12):2066-75.

PMID:
11117535
40.

Primary medical therapy of micro- and macroprolactinomas in men.

Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A.

J Clin Endocrinol Metab. 2000 Sep;85(9):3053-7.

PMID:
10999785
41.

A human pituitary tumor-derived folliculostellate cell line.

Danila DC, Zhang X, Zhou Y, Dickersin GR, Fletcher JA, Hedley-Whyte ET, Selig MK, Johnson SR, Klibanski A.

J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7.

PMID:
10720059
42.

Activin effects on neoplastic proliferation of human pituitary tumors.

Danila DC, Inder WJ, Zhang X, Alexander JM, Swearingen B, Hedley-Whyte ET, Klibanski A.

J Clin Endocrinol Metab. 2000 Mar;85(3):1009-15.

PMID:
10720031
43.

Expression of prolactin-releasing peptide and its receptor messenger ribonucleic acid in normal human pituitary and pituitary adenomas.

Zhang X, Danila DC, Katai M, Swearingen B, Klibanski A.

J Clin Endocrinol Metab. 1999 Dec;84(12):4652-5.

PMID:
10599733
44.

Supplemental Content

Loading ...
Support Center